Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Intellia Therapeutics, Inc. (38I.F)

6.98
+0.28
+(4.18%)
As of 3:49:30 PM GMT+2. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
57,877
57,877
36,275
52,121
33,053
Operating Expense
592,140
592,140
551,566
510,285
300,903
Operating Income
-534,263
-534,263
-515,291
-458,164
-267,850
Net Non Operating Interest Income Expense
47,807
47,807
49,832
8,542
1,283
Other Income Expense
-32,565
-32,565
-15,733
-24,564
-1,325
Pretax Income
-519,021
-519,021
-481,192
-474,186
-267,892
Net Income Common Stockholders
-519,021
-519,021
-481,192
-474,186
-267,892
Diluted NI Available to Com Stockholders
-519,021
-519,021
-481,192
-474,186
-267,892
Basic EPS
-5.45
-5.25
-5.42
-6.16
-3.78
Diluted EPS
-5.45
-5.25
-5.42
-6.16
-3.78
Basic Average Shares
95,998.50
98,849
88,770
76,972
70,894
Diluted Average Shares
95,998.50
98,849
88,770
76,972
70,894
Total Operating Income as Reported
-534,263
-534,263
-515,291
-458,164
-267,850
Total Expenses
592,140
592,140
551,566
510,285
300,903
Net Income from Continuing & Discontinued Operation
-519,021
-519,021
-481,192
-474,186
-267,892
Normalized Income
-486,456
-486,456
-481,092
-460,701
-267,892
Interest Income
47,807
47,807
49,832
8,542
1,283
Net Interest Income
47,807
47,807
49,832
8,542
1,283
EBIT
-534,263
-534,263
-515,291
-458,164
-267,850
EBITDA
-523,978
-523,978
-506,315
-450,592
-260,959
Reconciled Depreciation
10,285
10,285
8,976
7,572
6,891
Net Income from Continuing Operation Net Minority Interest
-519,021
-519,021
-481,192
-474,186
-267,892
Total Unusual Items Excluding Goodwill
-32,565
-32,565
-100
-13,485
--
Total Unusual Items
-32,565
-32,565
-100
-13,485
--
Normalized EBITDA
-491,413
-491,413
-506,215
-437,107
-260,959
12/31/2021 - 5/12/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

05Y.F Vivoryon Therapeutics N.V.
1.8120
-2.16%
 
F6T.F Fate Therapeutics, Inc.
1.1715
+2.14%
 
22UA.F BioNTech SE
87.00
-14.03%
 
GRCE Grace Therapeutics, Inc.
2.3900
+0.42%
 
DYN Dyne Therapeutics, Inc.
11.13
+0.14%
 
TPST Tempest Therapeutics, Inc.
7.92
-1.61%
 
OCGN Ocugen, Inc.
0.7183
-2.52%
 
CRSP CRISPR Therapeutics AG
38.51
-1.55%